To realize our corporate philosophy that “Kyorin continues to fulfill its mission of cherishing life and benefiting society by contributing to better health,” in 2010, the Kyorin Group formulated the HOPE100 long-term vision with a view toward 2023, the 100th anniversary of the founding of our core subsidiary, KYORIN Pharmaceutical Co., Ltd. The period through 2023 was divided into three stages (Stage 1: fiscal 2010-2015; Stage 2: fiscal 2016-2019; and Stage 3: fiscal 2020-2023), and medium-term business plans have been formulated for each stage with the aim of evolving into a company that is recognized internally and externally as a healthy “Company that supports sound and healthy lifestyles.”
Positioning of Medium-Term Business Plan "HOPE 100 -Stage 3-"
Basic Concept of Medium-Term Business Plan “Hope 100-Stage 3”
The ethical drugs business is currently facing an increasingly challenging external environment in the face of stepped-up government measures to contain costs for medical treatment and drugs, a higher degree of difficulty in new drug creation, and changes in activities of providing information. At the same time, internally we are creating the new drugs group that we expect to drive growth, and businesses including diagnostics are beginning to produce results, allowing us to view fiscal 2020 as the beginning of a period of growth. Against this backdrop, we are looking beyond previous concepts and ways of doing things and have formulated the HOPE100 -Stage 3- (fiscal 2020-2023) medium-term business plan to pursue “originality (unique competitive strength)” as we shift to a growth trend. In the form of a statement, the plan seeks to “realize a growth trend through the pursuit of originality,” as we move forward by pursuing our business strategy and organizational strategy to achieve the targets we have set.
Vision in Stage 3
Aim to become a globally recognized company through the creation of innovative new drugs. To this end, expand the new drugs business, GE business, infection-related business (prevention, diagnosis, and treatment of infections) in an integrated manner to widely support people’s health.
